Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Recombinant humanized anti-PD-1 monoclonal antibody in advanced melanoma
CTR20160900Phase 2Active
- Sponsor
- Junshi Biosciences
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in melanoma, sponsored by Junshi Biosciences. Started Feb 2017; status: active.
02
Drugs
toripalimab
03
Conditions
melanoma
Beyond the preview
Go deeper on CTR20160900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160900.